IL251619B - Preparations containing synergistic combinations of auristatin - Google Patents
Preparations containing synergistic combinations of auristatinInfo
- Publication number
- IL251619B IL251619B IL251619A IL25161917A IL251619B IL 251619 B IL251619 B IL 251619B IL 251619 A IL251619 A IL 251619A IL 25161917 A IL25161917 A IL 25161917A IL 251619 B IL251619 B IL 251619B
- Authority
- IL
- Israel
- Prior art keywords
- auristatin
- synergistic
- combinations
- synergistic auristatin
- auristatin combinations
- Prior art date
Links
- 108010044540 auristatin Proteins 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062192P | 2014-10-10 | 2014-10-10 | |
| PCT/IB2015/057457 WO2016055907A1 (en) | 2014-10-10 | 2015-09-29 | Synergistic auristatin combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251619A0 IL251619A0 (en) | 2017-06-29 |
| IL251619B true IL251619B (en) | 2020-10-29 |
Family
ID=54288858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251619A IL251619B (en) | 2014-10-10 | 2017-04-06 | Preparations containing synergistic combinations of auristatin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10617670B2 (OSRAM) |
| EP (2) | EP3204005A1 (OSRAM) |
| JP (1) | JP6784668B2 (OSRAM) |
| KR (1) | KR20170058432A (OSRAM) |
| CN (1) | CN107106685A (OSRAM) |
| AU (1) | AU2015329625B2 (OSRAM) |
| BR (1) | BR112017006113A8 (OSRAM) |
| CA (1) | CA2907878A1 (OSRAM) |
| IL (1) | IL251619B (OSRAM) |
| MX (1) | MX2017004580A (OSRAM) |
| RU (1) | RU2717570C2 (OSRAM) |
| WO (1) | WO2016055907A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3019559A4 (en) | 2013-08-22 | 2017-04-05 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| KR102530707B1 (ko) | 2016-04-01 | 2023-05-11 | 소니그룹주식회사 | 초휘도 이량체성 또는 중합체성 염료 |
| KR20180133890A (ko) | 2016-04-06 | 2018-12-17 | 소니 주식회사 | 스페이싱 링커 그룹을 포함하는 초고명도 이량체성 또는 중합체성 염료 |
| EP3455300A1 (en) | 2016-05-11 | 2019-03-20 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| EP3691689A1 (en) | 2017-10-05 | 2020-08-12 | Sony Corporation | Programmable dendritic drugs |
| JP7551056B2 (ja) | 2017-10-05 | 2024-09-17 | ソニーグループ株式会社 | プログラマブルなポリマー薬物 |
| WO2019088176A1 (ja) * | 2017-10-31 | 2019-05-09 | 国立大学法人神戸大学 | 抗体薬物複合体効果増強剤 |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| AU2018375787B2 (en) * | 2017-11-30 | 2023-02-23 | Ladrx Corporation | Albumin-binding prodrugs of auristatin E derivatives |
| WO2019140301A1 (en) | 2018-01-12 | 2019-07-18 | Sony Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| EP4616912A3 (en) | 2018-01-12 | 2025-11-19 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| KR102742386B1 (ko) | 2018-03-19 | 2024-12-16 | 소니그룹주식회사 | 형광 신호 향상을 위한 2가 금속의 사용 |
| WO2019182766A1 (en) | 2018-03-21 | 2019-09-26 | Sony Corporation | Polymeric tandem dyes with linker groups |
| KR102854332B1 (ko) | 2018-06-27 | 2025-09-03 | 소니그룹주식회사 | 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료 |
| KR102486779B1 (ko) | 2019-09-26 | 2023-01-12 | 소니그룹주식회사 | 링커 그룹을 갖는 중합체성 탠덤 염료 |
| JP7556194B2 (ja) * | 2019-12-13 | 2024-09-26 | Ｔｏｐｐａｎホールディングス株式会社 | 細胞構造体及びその使用 |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4846978B2 (ja) | 2001-10-30 | 2011-12-28 | メルク セローノ ソシエテ アノニム | タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ |
| PA8577501A1 (es) | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| NZ583292A (en) * | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| CA2621502A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| CN101542478B (zh) | 2006-06-26 | 2012-07-18 | 尼尔森（美国）有限公司 | 提高数据仓库性能的方法和装置 |
| HRP20110621T2 (hr) | 2006-09-15 | 2013-12-06 | Pfizer Products Inc. | SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3 |
| CL2008001334A1 (es) * | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| KR101601986B1 (ko) | 2007-10-02 | 2016-03-17 | 추가이 세이야쿠 가부시키가이샤 | 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제 |
| EP2300483A1 (en) * | 2008-05-23 | 2011-03-30 | Wyeth LLC | Triazine compounds as p13 kinase and mtor inhibitors |
| JP2013534520A (ja) * | 2010-06-08 | 2013-09-05 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| ES3004351T3 (en) | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| ES2596194T3 (es) | 2011-04-01 | 2017-01-05 | Wyeth Llc | Conjugados de anticuerpo-fármaco |
| CA2850034A1 (en) * | 2011-10-28 | 2013-05-02 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
| PT3327027T (pt) * | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| BR112015010436A2 (pt) * | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| PT3137114T (pt) * | 2014-04-30 | 2021-02-26 | Pfizer | Conjugados anticorpo-fármaco anti-ptk7 |
-
2015
- 2015-09-29 US US15/516,780 patent/US10617670B2/en active Active
- 2015-09-29 CN CN201580054253.XA patent/CN107106685A/zh active Pending
- 2015-09-29 BR BR112017006113A patent/BR112017006113A8/pt not_active Application Discontinuation
- 2015-09-29 EP EP15778051.1A patent/EP3204005A1/en not_active Withdrawn
- 2015-09-29 JP JP2017518541A patent/JP6784668B2/ja active Active
- 2015-09-29 EP EP19170411.3A patent/EP3549583A1/en not_active Withdrawn
- 2015-09-29 WO PCT/IB2015/057457 patent/WO2016055907A1/en not_active Ceased
- 2015-09-29 MX MX2017004580A patent/MX2017004580A/es unknown
- 2015-09-29 KR KR1020177010980A patent/KR20170058432A/ko not_active Ceased
- 2015-09-29 AU AU2015329625A patent/AU2015329625B2/en not_active Ceased
- 2015-09-29 RU RU2017112048A patent/RU2717570C2/ru active
- 2015-10-07 CA CA2907878A patent/CA2907878A1/en active Pending
-
2017
- 2017-04-06 IL IL251619A patent/IL251619B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017006113A8 (pt) | 2018-04-24 |
| CA2907878A1 (en) | 2016-04-10 |
| EP3549583A1 (en) | 2019-10-09 |
| US20180228769A1 (en) | 2018-08-16 |
| US10617670B2 (en) | 2020-04-14 |
| CN107106685A (zh) | 2017-08-29 |
| RU2017112048A (ru) | 2018-11-15 |
| RU2017112048A3 (OSRAM) | 2019-05-07 |
| WO2016055907A1 (en) | 2016-04-14 |
| BR112017006113A2 (pt) | 2017-12-19 |
| JP6784668B2 (ja) | 2020-11-11 |
| EP3204005A1 (en) | 2017-08-16 |
| RU2717570C2 (ru) | 2020-03-24 |
| IL251619A0 (en) | 2017-06-29 |
| AU2015329625A1 (en) | 2017-04-13 |
| AU2015329625B2 (en) | 2018-04-05 |
| KR20170058432A (ko) | 2017-05-26 |
| JP2017530983A (ja) | 2017-10-19 |
| MX2017004580A (es) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304663A (en) | combination | |
| IL251619A0 (en) | Preparations containing synergistic combinations of auristatin | |
| IL247073A0 (en) | combination | |
| PT3122358T (pt) | Combinações de inibidores do fgfr e cmet para o tratamento do cancro | |
| GB201501859D0 (en) | Composition | |
| GB201410905D0 (en) | Composition | |
| SG11201704735WA (en) | Composition | |
| ZA201704464B (en) | Composition | |
| GB201403017D0 (en) | Composition | |
| PL2905411T3 (pl) | Brama | |
| GB201414910D0 (en) | Composition | |
| GB201403561D0 (en) | Composition | |
| PL3217964T3 (pl) | Kompozycja | |
| GB201414555D0 (en) | Composition | |
| GB201410493D0 (en) | Composition | |
| GB201519442D0 (en) | Composition | |
| ZA201606127B (en) | Composition | |
| GB201420628D0 (en) | Composition | |
| GB201415483D0 (en) | Composition | |
| GB201400765D0 (en) | Self - Closing eyeguard | |
| GB201404390D0 (en) | Composition | |
| GB201402648D0 (en) | Composition | |
| IL250781A0 (en) | preparation | |
| GB201503484D0 (en) | Composition | |
| GB201502355D0 (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |